Home/Pipeline/HBM7575 (SKB575)

HBM7575 (SKB575)

Atopic Dermatitis

IND FiledActive (Global)

Key Facts

Indication

Atopic Dermatitis

Phase

IND Filed

Status

Active (Global)

Company

Harbour BioMed

About Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Metabolic Diseases

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active
NM26	Numab Innovation	Pre-clinical	Active